Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) View Full Press Release Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results